News from the BioCity Campus

Zellkraftwerk/Canopy Biosciences: Immune Profiling Platform continues to grow

The German-American company Zellkraftwerk / Canopy Biosciences merged with another partner in the USA at the end of 2019 and announced the acquisition of Core Diagnostics. The company is one of the leading CLIA-certified providers of biomarker analysis services for biopharmaceutical research.

dr Jan Detmers, Managing Director of Zellkraftwerk GmbH says: "By combining multi-omic technologies such as ChipCytometry, NanoString and RareSequencing, we create a unique and powerful platform for immune profiling of cells and tissues. Thanks to the merger with Core Diagnostics, we are now addressing more and more customers from the clinical area in addition to the preclinical and translational areas.”

With the acquisition of Core Diagnostics, Zellkraftwerk and Canopy Biosciences can now offer their services in the field of highly parametric cell and tissue analysis under the highly regulated CLIA conditions worldwide.

  1. Balachandran, CEO of Core Diagnostics commented:

"Through this cooperation, it is possible to provide customers with holistic support and to add individual services, so that we can meet the respective goals of the client. With Zellkraftwerk and Canopy we have found partners with whom we can expand our portfolio and serve our customers better. "

In addition to NanoString transcription proliferation, Core Diagnostics also offers histopathology services including immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH).

The acquisition is now the 2nd merger in a year and is seen as a targeted, strategic growth investment.

Information about cell power plant

Zellkraftwerk is a pioneer and driving force behind chip cytometry. The company has been working very successfully in the field of automated, highly parametric tissue and cell analysis since 2014. The innovative company, headquartered in Leipzig, has developed a unique hardware and software technology platform that is used successfully in a wide range of areas such as immuno-oncology, autoimmunity research and the development of cellular therapies. The products are used by academic research groups as well as pharmaceutical companies worldwide.

For more information, please visit

About Canopy Biosciences

Founded in 2016, Canopy Biosciences has rapidly built a comprehensive portfolio of products and services for gene editing, gene expression analysis and regulation, and bioprocessing. The Company's gene editing portfolio offers full-service, easy-to-use CRISPR kits and custom cell line technology. Headquartered in St. Louis, Missouri, Canopy Biosciences serves researchers at universities, research institutes, and biotechnology and pharmaceutical companies worldwide.

For more information, please visit

Information about Core Diagnostics

Core Diagnostics is a CLIA-licensed laboratory in California supporting biomarker analysis and translational research. The range of services extends from targeted basic research to certified sample analyzes from clinical phase III studies. Core's research group works with customers to develop biomarker strategies and assays. Core Diagnostics follows a technology-agnostic approach and offers services in the areas of histopathology, IHC, FISH, mutation analysis and high-throughput gene expression analysis.

For more information, please visit

Source: press release from Zellkraftwerk/Canopy Biosciences by 16.01.2020

previous news

University hospitals in Leipzig and Jena are developing a joint oncological center of excellence

Leipzig. The University Hospital Leipzig (UKL) and the University Hospital Jena (UKJ) plan to jointly develop a Comprehensive Cancer Center (CCC) funded by the German Cancer Aid. The partners have now signed a letter of intent. The University Cancer Center Leipzig (UCCL) at the UKL and the University Tumor Center (UTC) Jena are working together on the project.